Senior Management Team

Mr. Crowley became president and CEO of Amicus in January 2005, having served as a director since 2004. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was senior vice president at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in September 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He previously served in several senior management roles with the Bristol-Myers Squibb Company (BMS), including director of the Executive Committee for the U.S. Medicines Group, director of Business Strategy for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. Preceding his experience at BMS, Mr. Crowley worked as a business strategy consultant for Marakon Associates. Mr. Crowley began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham, Summers, Welsh & Spilman.

Mr. Crowley is involved with several charitable and community organizations, including serving on the Board of Directors of St. Peter's University Health Care System. Mr. Crowley's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease - a fatal neuromuscular disorder. Mr. Crowley and his family have been featured on the cover of The Wall Street Journal and on The Today Show, CNBC and The Paula Zahn Show on CNN. In 2006, Geeta Anand, Pulitzer prize winning writer for The Wall Street Journal, authored a book on Mr. Crowley entitled "The Cure: How a Father Raised $100 Million- and Bucked the Medical Establishment- in a Quest to Save His Children." (www.thecurebook.com).

Mr. Crowley is a commissioned officer in the United States Navy Reserve (active).

Mr. Crowley earned his B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School.

From 1981-2006, Mr. Hayden had a highly-successful 25 year career in pharmaceuticals and related health care businesses with Bristol-Myers Squibb Company. Since March of 2006, Mr. Hayden has held key leadership roles at several venture-stage pharmaceutical and biotech companies.

At Bristol-Myers Squibb, Mr. Hayden served as executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses with combined annual sales in excess of $10 billion as well as global pharmaceutical manufacturing. Prior to that, Mr. Hayden held a number of senior management positions including vice president and general manager of Mead Johnson Laboratories; president of Oncology and Immunology; senior vice president for Worldwide Franchise Management and Business Development; president of Intercontinental and senior vice president, Business Development, Pharmaceuticals; president of Worldwide Medicines; executive vice president of Strategy; and executive vice president of the Health Care Group.

Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Amicus Therapeutics, Transave Inhalation Biotherapeutics, Vitae Pharmaceuticals and Gloucester Pharmaceuticals as well as serving as a Director of Cogentus Pharmaceuticals.

Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

Mr. Patterson joined Amicus in December 2004 and currently serves as Chief Operating Officer. Mr. Patterson was promoted to Chief Operating Officer from Chief Business Officer in September 2006. Prior to Amicus, Mr. Patterson served as vice president of Regulatory Affairs, and later vice president of Commercial Planning at BioMarin Pharmaceutical. Mr. Patterson oversaw the development of Aldurazyme® (laronidase) for the treatment of the genetic disease MPS I and helped build the sales and marketing function for the company. Prior to BioMarin, Mr. Patterson worked at Genzyme Corporation in Manufacturing and Regulatory Affairs. While at Genzyme he contributed to the development and global licensing of multiple products.

Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.

Mr. Dentzer joined Amicus in September 2006 as Chief Financial Officer. He joined the company from Biogen Idec Inc. where he served as Corporate Controller from November 2003 to September 2006. Prior to the November 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation, Mr. Dentzer served as Corporate Controller of Biogen, Inc. Prior to Biogen, he served in a variety of financial positions at E. I. du Pont de Nemours and Company, most recently as Chief Financial Officer of DuPont Flooring Systems.

Mr. Dentzer received a B.A. from Boston College and an M.B.A. from the University of Chicago.

Dr. David Lockhart joined Amicus Therapeutics in January 2006 as chief scientific officer. He brings to Amicus 13 years of industry experience and achievements including credit as the primary developer of genome-wide gene-expression profiling with high-density DNA arrays when he was at Affymetrix.

Before coming to Amicus, Dr. Lockhart was president, CSO and co-founder of Ambit Biosciences in San Diego. He has served as director of genomics at the Genomics Institute of the Novartis Research Foundation, and he held various leadership positions during his more than five years at Affymetrix, including vice president of genomics research. Dr. Lockhart has also been a visiting scholar at the Salk Institute for Biological Studies.

Dr. Lockhart received his Ph.D. in Chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute at MIT under Professor Peter S. Kim. He has published nearly 60 peer-reviewed scientific articles on kinase technology, kinase inhibitor discovery, genomics and the use of genomic tools for important biological and biomedical problems.

Dr. Palling brings more than 20 years of drug development experience to Amicus and has served as senior vice president of Drug Development since the company began operations in August 2002. He has responsibility for preclinical development and manufacturing. Previously, he was vice president of Worldwide Assay Research and Development at Ortho Clinical Diagnostics, a Johnson & Johnson Company, and prior to that he served as senior director of Pharmaceutical Development at Johnson & Johnson Pharmaceutical Research and Development.

Prior to Johnson & Johnson, Dr. Palling worked at Hoffmann-La Roche where he held various management positions within Pharmaceutical Development. He was head of Analytical Research and Development, as well as an International Project Director leading multi-functional teams developing new medicines, primarily for oncology and virology.

Dr. Palling received B.Sc. and Ph.D. degrees in Chemistry from the University of London, King's College, and conducted post-doctoral research in Biochemistry at Brandeis University.

Dr. Licholai brings his experience in financing medical innovation, in clinical practice and in scientific research to his position overseeing Medical Affairs at Amicus. Prior to joining Amicus in 2004, he was a venture capitalist at Domain Associates, where he helped fund biotechnology and medical device start-up companies. Previously he was director of Ventures and Business Development for Medtronic Neurological, where he managed a global portfolio of novel drug delivery and neurological treatments for diseases such as Parkinson's disease, epilepsy, CNS malignancies and chronic pain syndromes.

Dr. Licholai trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. During his residency, Dr. Licholai also worked on hospital efficiency and merger strategies for Integral Consulting. He was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health. He did research in molecular genetics at Yale University and examined variants in hereditary blood diseases. Dr. Licholai also worked in molecular oncology at Rockefeller University. Additionally, while at Harvard Business School, he worked with Novartis and Millennium Pharmaceuticals. Dr. Licholai received his B.S. from Boston College and Pre-Medical studies at Columbia University, his M.D. from Yale Medical School and his M.B.A from Harvard Business School.

Nicole Schaeffer has overseen Human Resources and Leadership Development at Amicus since March 2005. She brings over eight years of experience building talent at early stage biotechnology companies. Prior to joining Amicus, Ms. Schaeffer worked at Flagship Ventures helping to start several high-tech/biotech companies including Adnexus Therapeutics, Epitome Biosystems and BG Medicine.

Ms. Schaeffer served as Director and later Senior Director of Human Resources for all three firms, responsible for all HR functions. Preceding her work with Flagship Ventures, Ms. Schaeffer rose from Manager to Director of Human Resources, responsible for all HR functions for Oak Industries, Inc., a publicly traded $450 million supplier of components to the communications industry. During her tenure, Oak Industries was acquired by Corning Inc. Ms. Schaeffer has also held a variety of human resources positions at EMC Corporation.

Ms. Schaeffer received her B.A. from the University of Rochester and her M.B.A. from Boston University.

Mr. Campbell joined Amicus in May 2006 as Senior Director of Business Development and became Vice President of Business Planning in April 2007. Prior to Amicus, Mr. Campbell served as director of Genzyme Cardiovascular, responsible for business strategy and development, commercial planning and alliance management for cardiac gene therapy programs. Previously, he was the Sr. Product Manager for Myozyme®, Genzyme's enzyme replacement therapy for Pompe disease. Mr. Campbell has also served in sales & marketing for Bristol-Myers Squibb, and as a business strategy consultant for Marakon Associates. Mr. Campbell is currently serving as the president of the National Tay-Sachs and Allied Diseases Association.

Mr. Campbell received his B.A. in Public Policy Studies from Duke University and his M.B.A. from Harvard Business School.

John Kirk joined Amicus Therapeutics in January 2008 as Vice President of Regulatory Affairs. John brings over 20 years of experience in Regulatory Affairs and has a proven track record in large scale, international regulatory issues and product approvals. Mr. Kirk was most recently Executive Director, Regulatory Affairs at Aegerion Pharmaceuticals and Director, Worldwide Regulatory Affairs at Pfizer Global Research & Development. In these positions John played a key role in several programs in the cardiovascular and inflammation therapeutic areas. Prior to Pfizer, John served as Senior Director, Regulatory Affairs at Esperion Therapeutics. Esperion was developing late stage compounds designed to mimic or enhance the reverse cholesterol transport function of HDL when it was acquired by Pfizer in 2003. At Esperion, John played a key role in the development and execution of regulatory strategies for these important developmental compounds. He brings significant expertise in several cardiovascular and metabolic related areas and has proven ability to contribute to the growth of early stage pharmaceutical companies as well as understanding U.S. and international regulatory processes required to create global registration strategies.

Andrew Shenker has served as Vice President of Clinical Research at Amicus since December 2007. Dr. Shenker is a physician scientist with a successful research career in pharmacology and molecular endocrinology and over 10 years of leadership experience in both academic and industry settings. From 2002 to 2007, Dr. Shenker was with Bristol-Myers Squibb where he served most recently as Medical Director in the Clinical Discovery group and led a team responsible for early clinical development and biomarker strategy for a novel antithrombotic drug. From 1995 to 2002, Dr. Shenker was Assistant Professor of Pediatrics, Molecular Pharmacology and Biological Chemistry at Northwestern University Medical School. Dr. Shenker has authored numerous publications on the role of gene mutations in G protein-coupled receptor signaling pathways in human disease.

Dr. Shenker received his undergraduate degree from Cornell University. He obtained his Ph.D. in Pharmacology and M.D. from the Mount Sinai School of Medicine in NYC, completed his internship and residency in Pediatrics at the Johns Hopkins Hospital, and was a post-doctoral fellow at the National Institutes of Health.